Merck licenses KRAS G12D inhibitor for $400 million in advance
Business

Merck licenses KRAS G12D inhibitor for $400 million in advance

By adminvoxa
September 29, 2026 1 Min Read
Comments Off on Merck licenses KRAS G12D inhibitor for $400 million in advance

In 2023, entrepreneur and synthetic chemist Tao Hu sold a KRAS inhibitor G12D to AstraZeneca. Today it sells another KRAS inhibitor G12D, this time…

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles and choose newsletters to go straight to your inbox.

Gn bussni

Post Views: 3
Author

adminvoxa

Follow Me
Other Articles